Nyxoah (STU:5YI) Moat Score: 4/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5YI Nyxoah SA STU:5YI
61 GF Score
Price €1.42
GF Value €23.34
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Nyxoah Moat Score?

Nyxoah STU:5YI -4.43% 61 Moat Score is 4 as of Jul. 15, 2026. GuruFocus rates STU:5YI with a GF Score™ of 61/100 and a GF Value™ of €23.34 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Nyxoah ranks better than 83.25% on this metric.

Nyxoah has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Nyxoah has Narrow Moat: Nyxoah SA has a discernible but modest moat due to its valuable intellectual property and patents in the medical device sector. However, it lacks strong brand strength and significant regulatory barriers to elevate it to a stronger moat status.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Nyxoah might have Narrow Moat - Discernible but modest moat.

Nyxoah  (STU:5YI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Nyxoah Moat Score Related Terms

STU:5YI vs ISRG, BDX, MDLN: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, Nyxoah's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nyxoah Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nyxoah's Moat Score distribution charts can be found below:

* The bar in red indicates where Nyxoah's Moat Score falls into.


STU:5YI
61GF Score
Nyxoah SA STU:5YI
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Nyxoah (STU:5YI) has a Moat Score of 4 as of Jul. 15, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Nyxoah ranks #141 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 16.7%.
Is Nyxoah's Moat Score too high?
Nyxoah's current Moat Score is 4. Based on the distribution chart, Nyxoah ranks #141 out of 842 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nyxoah has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nyxoah's Moat Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nyxoah ranks #141 out of 842 companies for Moat Score. This places Nyxoah in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Nyxoah's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nyxoah stock overvalued right now?
Based on GuruFocus' analysis, Nyxoah (STU:5YI) is currently considered Possible Value Trap. The stock's GF Value™ is €23.34, compared to a current price of €1.42 — trading 93.9% below its estimated fair value. The current Moat Score is 4. Nyxoah's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Nyxoah (STU:5YI), the current Moat Score is 4 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nyxoah (STU:5YI) Overvalued in 2026?

Based on GuruFocus' analysis, Nyxoah stock appears to be undervalued. The current stock price of €1.42 is trading 93.9% below its estimated GF Value™ of €23.34. GuruFocus considers Nyxoah to be Possible Value Trap.

Key valuation signals for STU:5YI:

  • Moat Score: 4
  • GF Value™: €23.34 vs. price of €1.42 (93.9% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the STU:5YI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nyxoah Business Description

Other Exchanges NYXH:USANYXH:Belgium
Address Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
61GF Score

Get the complete analysis for STU:5YI

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.42
Price
€23.34
GF Value